Literature DB >> 3560161

Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

G J Atwell, G W Rewcastle, B C Baguley, W A Denny.   

Abstract

The synthesis, physicochemical properties, and antitumor activity of a series of N-[2-(dialkylamino)alkyl]-acridine-4-carboxamides are reported. The compounds bind to DNA by intercalation, but exist under physiological conditions as monocations due to the weakly basic acridine chromophore (pKa = 3.5-4.5). The acridine-4-carboxamides show very broad structure-activity relationships (SAR) for antileukemic activity, with substituents at nearly all acridine positions proving acceptable. The compounds also show remarkable activity against the Lewis lung solid tumor in vivo, with several analogues capable of effecting 100% cures of the advanced disease. The broad SAR and high solid-tumor activity of the 9-acridine-4-carboxamides imply they should be considered as a completely new class of antitumor agent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3560161     DOI: 10.1021/jm00387a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  Synthesis of novel Eu(III) luminescent probe based on 9- acridinecarboxylic acid skelton for sensing of ds-DNA.

Authors:  Hassan A Azab; Belal H M Hussein; Abdullah I El-Falouji
Journal:  J Fluoresc       Date:  2011-11-09       Impact factor: 2.217

2.  Identification of compounds selectively killing multidrug-resistant cancer cells.

Authors:  Dóra Türk; Matthew D Hall; Benjamin F Chu; Joseph A Ludwig; Henry M Fales; Michael M Gottesman; Gergely Szakács
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

3.  A novel form of intercalation involving four DNA duplexes in an acridine-4-carboxamide complex of d(CGTACG)(2).

Authors:  A Adams; J M Guss; C A Collyer; W A Denny; L P Wakelin
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

4.  Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.

Authors:  W R Wilson; W A Denny; S M Pullen; K M Thompson; A E Li; L H Patterson; H H Lee
Journal:  Br J Cancer Suppl       Date:  1996-07

5.  Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.

Authors:  J W Paxton; D Young; S M Evans; P Kestell; I G Robertson; E M Cornford
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.

Authors:  G J Finlay; K M Holdaway; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans.

Authors:  J W Paxton; D Young; I G Robertson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse.

Authors:  J W Paxton; D Young; S M Evans; I G Robertson; P Kestell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.

Authors:  Azeem Saleem; Pat M Price
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

10.  Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

Authors:  Christian Dittrich; Veronique Dieras; Pierre Kerbrat; Cornelis Punt; Roberto Sorio; Francesco Caponigro; Xavier Paoletti; Christine de Balincourt; Denis Lacombe; Pierre Fumoleau
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.